drugset / Trial / NCT06290050
A Study of the Interaction of Other Drugs With TAK-279 in Healthy Adults
Non-randomizedSequentialOpen-labelOther
Summary
The main aim of this study is to find out how several doses of TAK-279 affects the body of healthy adults and processes midazolam and repaglinide (pharmacokinetics or PK). Another aim is to learn about the side effects of TAK-279 and how well it is tolerated when given to healthy adults either alone or together with midazolam or repaglinide. During the study, participants will need to stay at the clinic for 19 days. Blood samples will be taken at several timepoints during the study. The study drug will be given by mouth (orally).
Timeline
- Start
- 2024-03-29
- Primary completion
- 2024-05-03
- Completion
- 2024-05-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Midazolam | Small molecule | 2 mg | Oral |
| Subject | Repaglinide | Small molecule | 0.5 mg | Oral |
| Subject | Zasocitinib | Small molecule | — | Oral |
Indications
No indication recorded.